Clinical trial · Interventional
Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy
A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen
NCT00386087CI-TRIAL-00001518completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effectiveness of enzastaurin in the treatment of patients with metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Enzastaurin Hydrochloride | Drug | Enzastaurin | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine the effects of enzastaurin in the treatment of patients with breast cancer by measuring its ability to reduce the size of the tumor or prevent further increases in tumor size.
Secondary outcomes (3)
- measure
- To evaluate the length of time that enzastaurin is able to effect control of the disease.
- measure
- To evaluate the side effects of enzastaurin in patients with breast cancer
- measure
- To determine whether changes in laboratory tests of patients treated with enzastaurin is associated with the response of their tumors to the drug.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of metastatic breast cancer or recurrent breast cancer where surgery can not be done for curative intent * Have received prior therapy with an anthracycline (class of drugs) and a taxane (class of drugs). * Tumors must not be positive for HER2, but if positive, the treatment plan should not include further treatment with the drug Herceptin. * Disease that can be definitely measured on Cat Scans or other radiological tests. * May have received high dose chemotherapy for autologous stem cell support greater than or equal to 6 months of starting this study. Exclusion Criteria: * More than 2 chemotherapy regimens for metastatic or locally recurrent disease. * Have brain cancer from breast cancer * Pregnant or breastfeeding * Have an inability to swallow tablets * Within 6 months have had a serious heart condition
References
Publications (0)
Data not yet available
No reference posted for this study.